Intentionally Curated Nexus of Companies
Our strategic focus aims at fostering cross-venture support while designing streamlined drug development paths to achieve accelerated de-risking, value creation, and diversification, underscoring our commitment to rapidly advance innovative treatments for patients in need
Landmark BioVentures operates a highly efficient, accelerated lean business model, focusing on groundbreaking programs targeting critical intersections of neoplasm, uncontrolled inflammation, neovascularization, and fibrosis
Duhn Therapeutics
Lipid Based Immunotherapies
Duhn Therapeutics is a clinical-stage sole-in-class innate immune switcher company advancing lipid-based cancer immunotherapies with the mission is to bring new solutions to cancer patients by reshaping the immunological profile of their tumors
Carla Biotherapeutics
Adoptive Cell Therapies
Carla BioTherapeutics is advancing a platform of CAR-T cell therapies with lead program targeting hemopathies and solid tumors to improve tumor infiltration
Roca Therapeutics
Medicines Against Severe Retinal Disorders
Roca Therapeutics is a venture-backed company advancing first-in-class topical small molecule therapies to address exacerbated angiogenesis, inflammation and oxidative stress across ophthalmology disorders with high unmet needs
Kekkan Biologics
Novel Biologics Against Severe Neovascular and Fibrotic Disorders
Kekkan Biologics is a platform company developing first-in-class bispecific mAbs against a novel LVRF target involved in lymphatic and vascular angiogenesis, and PD-1
Elikya Therapeutics
Next-Gen ADC Design
Elikya Therapeutics is developing first-in-class toxic payloads for Antibody Drug Conjugates able to target both tumors and tumor micro-environment (fibrosis and vascularization) with both cytotoxic and immune mediated effects
SPIMA Therapeutics
Unlocking New Paths with Smart Peptides
SPIMA Therapeutics develops next-gen engineered therapeutic peptides to address undruggable protein-protein interactions
Massalia Therapeutics
Targeting Novel Paths to Halt Fibrotic Diseases and Cancers
Massalia Therapeutics is developing mono- and bispecific antibodies against novel SANF target involved in aggressive fibrotic conditions and treatment-resistant cancers